CuraSen Therapeutics Funding: $60M Raised, Series B (2024)
CuraSen Therapeutics is based in San Mateo. It has raised $60M in total funding. Latest round: Series B.
CuraSen Therapeutics funding overview
CuraSen Therapeutics is based in San Mateo. CuraSen Therapeutics has raised $60M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in August 2024. The round record for CuraSen Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include New Leaf Venture Partners, Longitude Capital, Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc., Pappas Capital and 2 others. 8 distinct backers are named across the disclosed rounds.
CuraSen Therapeutics at a glance
Total raised
$60M
Latest round
Series B
Latest round date
August 2024
Headquarters
San Mateo
Notable investors
New Leaf Venture Partners, Longitude Capital, Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc., Pappas Capital, Access Biotechnology, Domain Associates
Frequently asked about CuraSen Therapeutics funding
How much has CuraSen Therapeutics raised?
CuraSen Therapeutics has raised $60M in total disclosed funding across the rounds on record.
Who has invested in CuraSen Therapeutics?
New Leaf Venture Partners, Longitude Capital, Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc., Pappas Capital are named among the investors backing CuraSen Therapeutics.
What was the latest CuraSen Therapeutics funding round?
The most recent disclosed round is a Series B, announced in August 2024.
Where is CuraSen Therapeutics based?
CuraSen Therapeutics is based in San Mateo.
When did CuraSen Therapeutics last raise?
The last disclosed CuraSen Therapeutics round closed in August 2024 at Series B.
CuraSen Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in San Mateo below to benchmark round size and investor mix.
